Mast cell-tumor cell interactions: For or against tumour growth and metastasis?

Anticancer Research

Volumn 17, Issue 3 A, 1997, Pages 1541-1549

  Dimitriadou, V ^a   Koutsilieris, M ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Angiogenesis; Invasion; Mast cells; Metastasis; Tumor growth

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; HEPARIN; HISTAMINE; PROTEINASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL INTERACTION; CYTOTOXICITY; EXTRACELLULAR MATRIX; HISTAMINE RELEASE; HOST RESISTANCE; HYPOTHESIS; MAST CELL; METASTASIS; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

ANIMALS; CELL DIVISION; HISTAMINE; HUMANS; MAST CELLS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0030922493     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (141)

1. Kinet JP, Blank U, Brini A, Jouvin MH, Kuster H, Mejan O and Ra C: The high-affinity receptor for IgE: a target for therapy of allergic diseases. Int Arch Allergy Appl Immunol 94: 51-55, 1991.
2. Galli SJ: Biology of disease. New insights into "the riddle of the mast cells": microenviromental regulation of mast cell development and phenotypic heterogeneity. Lab Invest 62:5-33, 1990.
3. Metcalfe DD, Kaliner M and Donlon MA: The mast cell. CRC Crit Rev Immun 3: 23-74, 1981.
4. Kessler DA, Langer RS, Pless NA and Folkman J: Mast cells and tumor angiogenesis. Int J Cancer 18: 703-709, 1976.
5. Dvorak AM and Kissell S: Granule changes of human skin mast cells characteristic of piecemeal degranulation and associated with recovery during wound healing in situ. J Leuk Biol 49: 197-210, 1991.
6. Woodbury RG, Miller HRP, Huntley JF, Newlands GFJ, Palliser AC and Wakelin D: Mucosal mast cells are functionally active during spontaneous expulsion of intestinal nematode infections in rat. Nature 312: 450-452, 1984.
7. Woodbury RG and Miller HRP: Quantitative analysis of mucosal mast cell protease in the intestines of Nippostrongylus-infected rats. Immunol 46: 487-495, 1982.
8. Goldsmith P, McGarity B, Walls AF, Church MK, Millward-Sadler GH and Robertson DAF: Corticosteroid treatment reduces mast cell numbers in inflammatory bowel disease. Dig Dis Sci 35: 1409-1413, 1990.
9. Fox CC, Lichtenstein LM and Roche JK: Intestinal mast cell responses in idiopathic inflammatory bowel disease - Histamine release from human intestinal mast cells in response to gut epithelial proteins. Gig Dis Sci 38: 1105-1112, 1993.
10. Sugiura H, Maeda T and Uehara M: Mast cell invasion of peripheral nerve in skin lesions of a topic dermatitis. Acta Derm Venereol [Stockh] 74-76, 1992.
11. Horsmanheimo L, Harvima IT, Jarvikallio A, Harvima RJ, Naukkarinen A and Horsmanheimo M: Mast cells are one major source of interleukin-4 in atopic dermatitis. Br J Dermatol 131: 348-353, 1994.
12. Crisp AJ, Chapman CM, Kirkham SA, Schiller AL and Krane SM: Articular mastocytosis in rheumatoid arthritis. Arthritis and Rheumatism 27(8): 845-851, 1984.
13. Nadel JA: Biologic Effects of Mast Cell Enzymes. Am Rev Respir Dis 145:S37-S41, 1992.
14. Dimitriadou V, Henry P, Brochet B, Mathiau P and Aubineau P: Cluster Headache: Ultrastructural evidence for mast cell degranulation and interaction with nerve fibers in the human temporal artery. Cephalalgia 10: 221-228, 1990.
15. Dimitriadou V, Buzzi MG, Moskowitz MA and Theoharides TC: Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast cells. Neuroscience 44: 97-112, 1991.
16. Dimitriadou V, Buzzi MG, Theoharides TC and Moskowitz MA: Ultrastructural evidence for neurogenically mediated changes in blood vessels of the dura mater and tongue following antidromic trigeminal stimulation. Neuroscience 1992.
17. Endo Y, Kikuchi T, Nakamura M and Shinoda H: Determination of histamine and polyamines in calcified tissues of mice: Contribution of mast cells and histidine decarboxylase to the amount of histamine in the bone. Calcif Tissue Int 57: 67-71, 1992.
18. Fallon MC, Whyte MP, Graig B and Teitelbaum SL: Mast cell proliferation in postmenopausal osteoporosis. Calcif Tissue Int 35: 29-31, 1983.
19. Hills E, Dunstan CR and Evans RA: Bone metabolism in systemic mastocytosis. J Bone Joint Surg 63A: 665-669, 1981.
20. Lindholm R, Lindholm S, Liukko P, Isokanta S, Rossi R, Autio E and Tamminen E: The mast cell as a componenet of callus in healing fractures. J Bone Joint Surg 51B: 148-155, 1969.
21. Mckenna MJ and frame B: The mast cell and bone. Clinical Orthopedics and Related Research 200:226-233, 1985.
22. Severson AR: Mast cells in areas of experimental bone resorption and remodeling. Br J Exp Pathol 50: 17-21, 1969.
23. Flynn EA and Schwartz G: Sequential mast cell infiltration and degranulation during experimental carcinogenesis. J Cancer Res Clin Oncol 117: 115-122, 1991.
24. Csaba G, Acs T, Horvath C and Mold K: Genesis and function of mast cells. Mast cells and plasmacyte reaction to induced homologous and heterologous tumours. Br J Cancer 15:327-335, 1961.
25. De Cidre LL and Sacerdote de Lustig E: Mast cell kinetics during tumor growth. Tumor Biol 11: 196-201, 1990.
26. Dvorak AM, Mihm MC. Osage JE and Dvorak HF: Melanoma. An ultrastructural study of the host inflammatory and vascular responses. Jf Invest Dermatol 75: 388-393, 1980.
27. Cawley EP and Hoch-Ligeti C: Association of tissue mast cells and skin tumors. Arch Dermatol 83: 146-150, 1961.
28. Mikhail GR and Miller-Milinska A: Mast cell population in human skin. J Invest Dermatol 43: 249-254, 1964.
29. Dvorak AM: Mast cell hyperplasia and degranulation in Crohn's disease. 657-662, 1979.
30. Lashner BA: Risk factors for small bowel cancer in Crohn's disease. Dig Dis Sci 37: 1179-1184, 1992.
31. Dunn MR and Montgomery POB: A study of the relationship of mast cells to carcinoma in situ of the uterine cervix. Lab Invest 6: 542-546, 1957.
32. Graham RM and Graham JB: Mast cells and cancer of the cervix. Surgery, Gynecology and Obstetrics 123: 3-9, 1966.
33. Dabbous MK, Walker R, Haney L, Carter LM, Nicolson GL and Woolley DE: Mast cells and matrix degradation at sites of tumour invasion in rat mammary adenocarcinoma. Br J Cancer 54: 459-465, 1986b.
34. Hartveit F, Thoresen S, Tangen M and Maartmann-Moe H: Mast cell changes and tumor dissemination in human breast carcinoma. Invasion Metastasis 4: 146-155, 1984.
35. Hartveit F: Mast cells and metachromasia in human breast cancer: their occurrence, significance and consequence: a preliminary report. J Pathol 134: 7-11, 1981.
36. Hartveit F and Sandstad E: Stromal metachromasia: a marker for areas of infiltrating tumour growth? Histopathol 6: 432-438, 1982.
37. Dethlefsen SM, Matsuura N and Zetter BR: Mas cell accumulation at sites of murine tumor implantation: Implications for angiognesis and tumor matastasis. Invasion and Metastasis 14: 395-408, 1995.
38. Aaltomaa S, Lipponen PK, Eskelinen MJ, Kosma V-M, Marin S, Alhava E and Syrjanen K: Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer 25: 895-864, 1992.
39. Elston CW, gresham GA and Rao GS: The cancer research campaign (King's/Cambridge) trial for early breast cancer. Br J Cancer 45: 655-669, 1982.
40. Ghiara P, Boraschi D, Villa L, Scapigliati G, Taddei C and Tagliabue A: In vitro generated mast cells express natural cytotoxicity against tumour cells. Immunol 55: 317-324, 1985.
41. Parwaresch MR, Horny HP and Lennert K: Tissue mast cells in health and disease. Path Res Pract 179: 439-461, 1985.
42. Dvorak AM, Galli SJ, Hammond ME, Churchill WH and Dvorak HF: Tumor-basophil interactions in vitro: a scanning and electron microscopy study. J Immunol 122: 2447-2457, 1979.
43. Farram E and Nelson DS: Mouse mast cell as antitumor effector cells. Cell Immunol 52: 294-301, 1980.
44. Henderson WR, Chi EY, Jong.E.C. and Klebanoff SJ: Mast cell-mediated tumor cell cytotoxicity. Role of the peroxidase system. J Exp Med 153: 520-524, 1981.
45. Tharp MD, Kasper C, Thiele D, Charley MR, Kennerly PA and SullivanTJ: Studies of connective tissue mast cell-mediated cytotoxicity. J Invest Dermatol 93: 423-428, 1989.
46. Benyon RC, Bissonnette EY and Befus AD: Tumor necrosis factor-alpha- dependent cytotoxicity of human skin mast cells is enhanced by anti-IgE antibodies. J Immunol 147: 2253-2258, 1991.
47. Tanooka H, Kitamura Y, Sado T, Tanaka K, Nagase M and Kondo S: Evidence for involvement of mast cells in tumor suppression in mice. J Nat Cancer Inst 69: 1305-1309, 1982.
48. Burtin C, Ponvert C and Fray A: Inverse correlation between tumor incidence and tissue histamine levels in W/WV, WV/+ and +/+ mice. J NatCancer Inst 74: 671-674, 1985.
49. Schitteck A, Abon Issa H, Stafford JH, Young D, Zwilling B and James AG: Growth of pulmonary metastases of B16 melanoma in mast cell-free mice. J Surg Res 38: 24-28, 1985.
50. Nordlund JJ and Askenase P: The effect of histamine, antihistamines, and a mast cell stabilizer on the growth of cloudman melanoma cells in DBA/2 mice. J Invest Dermatol 81: 28-31, 1983.
51. Roche WR: Mast cells and tumors. The specific enhancement of tumor proliferation in vitro. Am J Pathol 119:57-64.1985.
52. Norrby K: Evidence of mast cell histamine being mitogenic in intact tissue. Agents and Actions 16: 3-4, 1985.
53. Dabbous M, Woolley DE, Haney L, Carter LM and Nicolson GL: Host-mediated effectors of tumor invasion: role of mast cells in matrix degradation. Clin Expl Metastasis 4: 141-152,1986a.
54. Farnoush A and McKenzie IC: Sequential histological changes and mast cell response in skin during chemically-induced carcinogenesis. J Pathol 12: 300-307, 1983.
55. Dabbous MK, Haney L, Nicolson GL, Eckley D and Woolley DE: Mast cell modulation of tumour cell proliferation in rat mammary adenocarcinoma 13762NF. Br J Cancer 63: 873-878,1991.
56. Farnoush AM, IC: Proliferation of mast cells in normal and DMBA-treated mouse skin. J Oral Pathol 13: 359-365, 1984.
57. Claudatus JCJ, d'Ovidio R, Lospalluti M and Meneghini CL: Skin tumors and reactive cellular infiltrate: further studies. Acta Derm Venereol 66: 29-34, 1986.
58. Roche WR: The nature and significance of tumour-associated mast cells. J Pathol 148: 175-182, 1986.
59. Schwartz LB: Mediators of human mast cells and human mast cell subsets. Annals of Allergy 58: 226-235, 1987.
60. Schwartz LB, Bradford TR, Irani AMA, DeBlois G and Craig SS: The major enzymes of human mast cell secretory granules. Am Rev Respir Dis 135: 186-189,1987.
61. Schwartz LB, Riedel C, Schratz J and Austen KF: Localization of carboxypeptidase A to the macromoleculur heparin proteoglycan-protein complex in secretory granules of rat serosal mast cells. J Immunol 128: 1128-1133,1982.
62. Stevens RL and Austen KF: Recent advances in the cellular and molecular biology of mast cells. Immunology Today 10: 381-386, 1989.
63. Bradding P, Feather IH, Howard PH, Mueller R, Roberts JA, Britten K, Bews JPA, Hunt TC, Okayama Y, Heusser CH, Bullock GR, Church MK and Holgate ST: Interleukin-4 is localised to and released by human mast cells. J Exp Med 176: 1381-1385, 1992.
64. Bradding P, Feather IH, Wilson S, Bardin PG, Heusser CH, Holgate ST and Howarth PH: Immunolocalization of cytokines in the nasal mucosa of normal and perennial rhinitic subjects: the mast cell as a source of 11-4, IL-5 and IL-6 in human allergic mucosal inflammation. J Immunol 151: 3853-3855, 1993.
65. Gordon JR and Galli SJ: Mast cells as a source of both preformed and immunologicully inducible TNF-alpha/cachectin. Nature 346: 274-275, 1990.
66. Qu Z, Liebler JM. Powers MR, Galey T, Ahmadi P, Huang XN, Ansel JC Butterfield JH. Plank SR and Rosenbaum JT: Mast cells are amajor source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma. Am J Pathol 147: 564-573, 1995.
67. Reed JA. Albino AP and McNutt NS: Human cutaneous mast cells express basic fibroblast growth factor, Lab Invest 72: 215-222, 1995.
68. Pennington DW, Lopez AR. Thomas PS. Peck C and Gold WM: Dog mastocytoma cells produce transforming growth factor betal. J Clin Invest 90: 35-41,1992.
69. Folkman J: How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Research 46: 467-473, 1986.
70. Starkey JR, Crowle PK and Taubenberger S: Mast cell-deficient w/w mice exhibit a decreased rate of tumor angiogenesis. Int J Cancer 42: 48-52, 1988.
71. Norrby K, Jakobsson A and Sorbo J: Mast cell secretion and angiogenesis, a quantitative study in rats and mice. Virchows Arch B Cell Pathol 57: 251-256, 1989.
72. Norrby K, Jakobsson A and Sorbo J: Mast cell mediated angiogenesis: a novel experimental model using the rat mesentery. Virchows Arch B Cell Pathol 52: 195-206, 1986.
73. Goodfield M, Hull SM, Holland D, Roberts G, Wood E, Reid S and Cunliffe W: Investigations of the 'active' edge of plaque psoriasis: Vascular proliferation precedes changes in epidermal keratin. Br J Dermatol 131: 808-813, 1994.
74. Michaelsson G, Hagforsen E and Lundin IP: The number of mast cells is highly increased in noninvolved skin in psoriasis. Acta Derm Venereol [Stockh] 75: 169,1995.
75. Naukkarinen A, Harvima IT, Aalto ML, Harvima RJ and Horsmanheimo M: Quantitative analysis of contact sites between mast cells and sensory nerves in cutaneous psoriasis and lichen planus based on a histochemical double staining technique. Arch Dermatol Res 283: 433-437, 1991.
76. Dvorak AM, Mihm MCJ and Dvorak HF: Morphology of delayed-type hypersensitivity reactions in man. ll. Ultrastructural alterations affecting the microvasculature and the tissue mast cells. Lab Invest 34: 179-187, 1976.
77. Dvorak H: Role of the basophilic leukocyte in allograft rejection. J Immunol 106: 279-282, 1971.
78. Smith SS and Basu PK: Mast cells in corneal immune reaction. Can J Ophtalmol 5: 175-179, 1970.
79. Folkman J, Taylor S and Spillberg C: The role of heparin in angiogenesis. In: Development of the vascular system (Ciba Foundation Symposium 100). London, Pitman Books, 1983, pp 132-149.
80. Folkman J: Regulation of angiogenesis: a new function of heparin. Biochemical Pharmacology 43: 905-909,1985.
81. Folkman J: Angiogenesis and breast cancer. J Clin Oncol 72: 441-443.1994.
82. Norrby K and Zettergren L: Tumour Burden stimulates autogenous mast cell-mediated angiogenesis. Agents Actions 38: C169-C171, 1993.
83. Azizkhan RG, Azizkhan JC, Zelter BR and Folkman J: Mast cell heparin stimulates migration of capillary endothelial cells in vitro, J Exp Med 252: 931-943,1980.
84. Folkman J and Brem H: Angiogenesis and Inflammation. In: Inflammation: Basic principles and clinical correlates (Gallin JI, Goldstein IM. Snyderman R, eds). New York, Raven Press, 1992, pp 821-839.
85. 125I] (Tyr10) FGF (1-10) by serum in vitro and involvement in the determination of circulating FGF by RIA. Biochem Biophys Res Commun 145: 775-781, 1987.
86. Chodak GW. Hospelhorn V, judge SM, Mayforth R, Koeppen H and Sasse J: Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer. Cancer Res 48: 2083-2088, 1988.
87. Kowalski J, Kwan HH, Prionas SD, Allison AC and Fajardo LF: Characterization and applications of the disc angiogenesis system. Exp Mol Pathol 56: 1-9,1992.
88. Hori A, Sasada R, Matsutani E, Naito K, Sakura Y, Fujita T and Kozai Y: Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against basic fibroblast growth factor. Cancer Res 51: 6180-6184, 1991.
89. Gospodarowicz D and Cheng J: Heparin protects basic and acidic FGF from inactivation. J Cell Physiol 128: 475-484, 1986.
90. Reed JA, Albino AP and Mcnutt NS: Human cutaneous mast cells express basic fibroblast growth factor. Lab Invest 72: 215-222,1995.
91. Markwardt F and Klocking HP: Heparin-induced release of plasminogen activator. Haemostasis 6: 370-374,1977.
92. Roche WR: Mast cells and tumour angiogenesis: the tumour-mediated release of an endothelial growth factor from mast cells. Int J Cancer 36: 721 -728.1985.
93. Auerbach W and Auerbach R: Angiogenesis inhibition: a review. PharmTher 63: 265-311, 1994.
94. Gruber BL, Marchese MJ. Suzuki K, Schwartz LB, Okada Y, Nagase H and Ramamurthy NS: Synovial procollagenase activation by human mast cell tryptase dependance upon matrix metallproteinase 3 activation. J Clin Invest 84: 1675-1662, 1989.
95. Yoffe JR, Taylor DJ and Woolley DE: Mast cell products stimulate collegenase and prostaglandin E production by cultures of adherent rheumatoid synovial cells. Biochem Biophys Res Commun 722: 270-276, 1984.
96. Yoffe JR, Taylor DJ and Wooley DE: Mast cell products and heparin stimulate the production of mononuclear-cell factor by cultured human monocyte/macrophage. Biochem J 230: 83-86,1985.
97. Woolley DE, Taylor DJ and Yoffe JR: Mammalian collagenases: aspects of regulation. Life Chem-Rep 2: 181-184,1984.
98. Dabbous MK, North SM, Haney L, Tipton DA and Nicolson GL: Effects of mast cell-macrophage interactions on the production of collagenolytic enzymes by metastatic tumor cells and tumor-derived and stromal fibroblasts. Clin Exp Metastasis 13: 33-41, 1995.
99. Gruber BL, Marchese MJ, Suzuki K, Schwartz LB, Okada Y, Nagase H and Ramamurthy NS: Synovial procollagenase activation by human mast cell tryptase: dependance upon matrix metalloproteinase 3 activation. J Clin Invest 84: 1657-1660, 1989.
100. Mican JM and Metcalfe DD: Arthritis and mast cell activation. J All Clin Immunol 86: 677-683, 1990.
101. Kielty CM, Lees M, Shuttleworth CA and Wooley D: Catabolism of intact type VI collagen microfibrils: susceptibility to degradation by serine proteases. Biochem Biophys Res Commun 191: 1230- 1232, 1993.
102. Lohi J, Harvima I and Keski-Oja J: Pericellular substrates of human mast cell tryptase: 72,000 dalton gelalinase and fibronectin. J Cell Biochem 50: 337-340,1992.
103. Rubinstein I, Nadel JA. Graf PD and Caughey GH: Mast cell chymase potentiates histamineinduced weal formation in the skin of rag weed-allergic dogs. J Clin Invest 86: 555-559, 1990.
104. Saarinen J, Kalkkinen N, Welgus HG and Kovanen PT: Activation of human interstitial procollagenase through direct cleavage of the Leu(83)-Thr(84) bond by mast cell chymase. J Biol Chem 269: 18134-18140, 1994.
105. Vartio T, Seppa H and Vaheri A: Susceptobility of soluble and matrix fibroneclins to degradation by tissue proteases, mast cell chymase and cathepsin G. J Biol Chem 256: 471 -477, 1981.
106. Banovac K, Banovac F, Yang J and Koren E: interaction of osteoblasts with extracellular matrix Effect of mast cell chymase. Proc Soc Exp Biol Med 203: 221 -235, 1993.
107. Brandes W, Beecroft WA and Hogg GR: Stimulation of in vivo tumor growth and phorbol esterinduced inflammation by N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine HCI. a potent ligand for intracellular histamine receptors. Biochem Biophys Res Commun 1791297-1304, 1991.
108. Franzen L and Norrby K: Local mitogenic effect of tissue mast cell secretion. Cell Tissue Kinet 13: 635-642,1980.
109. Whitehead RJ. Taylor D, Evanson J, Hart I and Woolley D: Demonstration of histamine H2 receptors on human melanoma cells. Biochem Biophys Res Commun 151: 518-523, 1988.
110. Davio CA. Cricco GP, Bergoc RM and Rivera ES: HI and H2 histamine receptors in human mammary carcinomas. Agents and Actions 38,special issue C172-C174, 1993.
111. Laboise C, Augeron C, Couturier-Turpin M, Gespach C, Cheret A and Potet F: Characterization of a newly established human gastric cancer line HGT-1 bearing histamine H2 receptors. Cancer Res 42: 1541-1548.1982.
112. Cricco GP, Davio CA. Martin G, Engel N, Fiksimons CP. Bergoc RM and Rivera ES: Histamine as an autocrine growth factor in experimental mammary carcinomas. Agents Actions 43 17-20, 1994.
113. Naslinski C and Kierska D: Histamine in C3H/W mice carrying spontaneous tumors of the mammary gland. Agents Actions 33: 192-194,1991.
114. Andersson A, Henningsson S, Lundell L and Rosengren E: Diamines and polyamines in DMBA induced breast carcinoma containing mast cells resistant to compound 48/80. Agents Actions 6/5: 577-583,1976.
115. Garcia-Caballero M, Neugebauer E, Rodriguez F, Nunez de Castro I, Heredia A, Costing E and Vara-Thorbeck C: Changes in histamine synthesis, tissue content and catabolism in human breast cancer. Agents Actions 27: 227-231,1989.
116. Watanabe T, Taguchi Y, Sasaki K, Tsuyama K and Kitamura Y: Increase in histidine decarboxylase activity in mouse skin after application of the tumor promoter tetradecanoylphorbol acetate. Biochem Biophys ResCommun 100: 427-432, 1981.
117. Ponvert C, Galoppin L and Canu P: Modifications in tissue histamine levels in mast cell- deficient mice (W/W-v) and in their littermates (W-v/+. W/+ and +/+) grafted with a methylcho-lanthrene-induced fibrosarcoma: Correlation with tumour rejection. Cancer Lett 85: 125-131, 1994.
118. Fisher ER and Fisher B: Role of mast cells in tumor growth. Arch Pathol 79: 185-191, 1965.
119. Burtin C, Scheinmann P, Salomon JC, Lespinats G and Canu P: The influence of intraperitoneal injections of histamine on tumour growth in fibrosarcoma-bcaring mice. Cancer Lett 12: 195-201, 1981.
120. Burtin C, Scheinmann P, Salomon JC, Lespinats G and Canu P: Decrease in tumour growth by injections of histamine or serotonin in fibrosarcoma-bearing mice, influence of HI and H2 receptors. Br J Cancer 45: 54-60, 1982.
121. Osband ME, Shen YJ and Schlesinger M: Successful tumour immunotherapy with cimetidine in mice. Lancet 1: 636-638,1981.
122. Glifford RRM, Ferguson RM. and Voss BV: Cimetidine reduction of tumour formation in mice. Lancet 1: 638-640, 1981.
123. Burtin C, Scheinmann P, Fray A, Lespinats G, Noirot C and Paupe J: Ranitidine and cancer. N Engl J Med 310: 1603, 1984.
124. Burtin C, Noirot C, Scheinmann P, Galoppin L, Sabolovic D and Bernard P: Clinical improvment in advanced cancer disease after treatment combining histamine and H2-antihistaminincs (ranitidine or cimetidine). Eur J Cancer Clin Oncol 24:161 -167, 1988.
125. Hellstrand K, Naredi P, Lindner P, Lundhulm K, Rudenstam CM, Hermodsson S, Asztely M and Hafstrom L: Histamine in immunotherapy of advanced melanoma: A pilot study. Cancer Immunol Immunother 39: 416-419, 1994.
126. Suonio E, Tuomisto L and Alhava E: Effects of histamine, H-1, H-2 and H-ic receptor antagonists and alpha-fluoromethylhistidine on the growth of human colorectal cancer in the subrenal capsule assay. Agents Actions 41: C118-C120,1994.
127. Adams WJ, Lawson JA and Morris DL: Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth. Gut 35: 1632-1636, 1994.
128. Kikuchi Y, Oomori K and Kato K: Effects of cimetidine on growth and immune function in nude mice bearing human ovarian carcinoma. J Nat Cancer Inst 74: 495-498,1985.
129. Armitage JO and Sidner RD: Antitumor effect of cimetidine. Lancet 1: 882-883, 1979.
130. Griswold D, Alessi S, Badger A, Poste G and Hanna N: Inhibition of T suppressor cell expression by histamine type 2 (H2) receptor antagonists. J Immunol 232: 3054-3057, 1984.
131. Sorbo J, Jakobsson A and Norrby K: Mast cell histamine is angiogenic through receptors for histamine 1 and histamine2. Int J Exp Path 75: 43-50, 1994.
132. Norrby K: Evidence of a dual role of endogenous histamine in angiogenesis. Int J ExpPath 76: 87-92,1995.
133. Woolley DE, Eckley D, Tetlow LC and Whitehead RJ: Effect of Mast Cell Products and Histamine on the Proliferative Behaviour of Human Melanoma and Carcinoma Cells In vitro. Agents Actions 38: C182-C184, 1993.
134. Nakamura K, Tanaka T, Morita E, Kameyoshi Y and Yamamoto S: Enhancement of fibroblast dependent mast cell growth in mice by a conditioned medium of keratinocyte-derived squamous cell carcinoma cells. Arch Dermatol Res 287: 91-96. 1994.
135. Valent P: The riddle of the mast cell: kit(CD117)-ligand as the missing link? Immunol Today 75: 111-114,1994.
136. Turner A, Zsebo K, Martin F, Jacobsen F, Bennett L and Broudy V: Nonhematopoietic tumor cell lines express stem cell factor and display c-kit receptors. Blood 80: 374-381, 1992.
137. Hines SJ, Organ C, Kornstein MJ and Krystal GW: Coexpression of the c-kit and stem cell factor genes in breast carcinomas. Cell Growth Differentiation 6: 769-779,1995.
138. Galli SJ, lemura A, Garlick DS, Gambavitalo C, Zsebo KM and Andrews RG: Reversible Expansion of Primate Mast Cell Populations In vivo by Stem Cell Factor. J Clin Invest 91: 148-152, 1993.
139. Nilsson G, Butterfield JH, Nilsson K and Siegbahn A: Stem cell factor is a chemotactic factor for human mast cells. J Immunol 153: 3717-3723, 1994.
140. Gruber BL, Marchese MJ and Kew RR: Transforming growth factor-beta 1 mediates mast cell chemotaxis. J Immunol 152: 5860-5867,1994.
141. Gruber BL, Marchese MJ and Kew R: Angiogenic factors stimulate mast cell migration. Blood 56: 2488-2493, 1995.